SymBio in 2 minutes
Unchanging philosophy of "Symbiosis"
Based on the philosophy of to co-create and to co-exist, we are working hard to develop groundbreaking new drugs.
Taking on Underserved Therapeutic Areas
We are currently developing brincidofovir, focusing our management resources on the treatment of post-transplant viral infections, blood cancers, solid cancers, and neurodegenerative diseases.
Outstanding new drug development and commercialization capabilities
The anti-cancer drug TREAKISYM, introduced in 2005, achieved early approval in just five years and has become the standard treatment for malignant lymphoma in Japan.
Leveraging our speedy new drug development and commercialization capabilities through our unique business model, we are working on the global development of "brincidofovir."
Breakthrough new drug candidate "brincidofovir"
Brincidofovir, an injectable antiviral drug introduced in 2019, possesses the rare characteristic of exhibiting high antiviral efficacy against many types of viruses. This characteristic has attracted the attention of numerous research institutions, and collaborative research is underway with academia and research organizations worldwide. Furthermore, its antitumor effect, discovered during the research process, has led to its development as a cancer treatment, and research and development is currently progressing in three areas: post-transplant viral infections, solid tumors, and neurodegenerative diseases.
| Joint research destination | Research disease | |
|---|---|---|
| Post-transplant infection | Penn State College of Medicine | Polyomavirus: Post-kidney transplant infection leading to progressive multifocal leukoencephalopathy (PML) |
| Blood cancers and solid tumors | National Institute of Infectious Diseases and Allergy (NIAID) | EB virus: Lymphoproliferative disorder (LPD) |
| University of California, San Francisco | Malignant brain tumors (glioblastoma) | |
| National Cancer Centre Singapore (NCCS) | EB virus: Lymphoma | |
| Neurodegenerative diseases | National Institute of Neurological Disorders and Stroke (NINDS) | JC virus: Progressive multifocal leukoencephalopathy (PML) |
| National Institute of Neurological Disorders and Stroke (NINDS) | EB virus: Multiple sclerosis (MS) | |
| Tufts University | HSV-1: Alzheimer's disease (AD) |
Brincidofovir is being developed in parallel
Because it is expected to be effective against many types of viruses, we are currently developing it simultaneously in three disease areas.
First, we plan to concentrate our resources on developing a treatment for adenovirus infection after hematopoietic stem cell transplantation, and we have started Phase III clinical trials in five major European countries: Germany, France, Italy, Spain, the United Kingdom, and the United States, starting in November 2025.
Furthermore, a Phase II clinical trial for progressive multifocal leukoencephalopathy (PML) was initiated in 2026 under the leadership of the National Institutes of Health (NIH).
Furthermore, in addition to its high antiviral activity, BCV has also been shown to have antitumor effects, and we are exploring new indications in the field of solid tumors through collaborative research with research institutions in various countries.
We will proceed with preparations to begin clinical trials for three types of cancer: malignant brain tumors (glioblastoma, glioblastoma), head and neck cancer, and EB virus-associated gastric cancer.
Aiming to become a global specialty pharmaceutical company.
Brincidofovir is currently conducting research and development with world-class research institutions, aiming to maximize business value by producing research results.
As a result, we aim to achieve a "50-50 in 2030" goal, where domestic and international sales are 50:50 by 2030, and become a truly global specialty pharmaceutical company.